Epilepsy is well-recognized as a disorder of brain networks. There is a growing body of
research to identify critical nodes within dynamic epileptic networks with the aim to target …

Objective There are three neurostimulation devices available to treat generalized epilepsy:
vagus nerve stimulation (VNS), deep brain stimulation (DBS), and responsive …

Neuromodulation is a key therapeutic tool for clinicians managing patients with drug‐
resistant epilepsy. Multiple devices are available with long‐term follow‐up and real‐world …

Objective Deep brain stimulation (DBS) can reduce seizures in Lennox–Gastaut syndrome
(LGS). However, little is known about the optimal target and whether efficacy depends on …

Neuromodulation (neurostimulation) is a relatively new and rapidly growing treatment for
refractory epilepsy. Three varieties are approved in the US: vagus nerve stimulation (VNS) …

OBJECTIVE Neuromodulation of the centromedian nucleus of the thalamus (CM) has
unclear effectiveness in the treatment of drug-resistant epilepsy. Prior reports suggest that it …

Generalized epilepsy affects 24 million people globally; at least 25% of cases remain
medically refractory. The thalamus, with widespread connections throughout the brain, plays …

Direct cortical stimulation has been applied in epilepsy for nearly a century and has
experienced a renaissance, given unprecedented opportunities to probe, excite, and inhibit …

Idiopathic generalized epilepsy (IGE) is a common type of epilepsy and despite an increase
in the number of available anti-seizure medications, approximately 20-30% of people with …

ABSTRACT Introduction Lennox-Gastaut syndrome (LGS) is a severe childhood-onset
epileptic encephalopathy, characterized by multiple seizure types, generalized slow spike …